Browse by author
Lookup NU author(s): Professor Alan Calvert, Dr Martin Highley, Professor John LunecORCiD, Professor Alan Boddy
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
In this pharmacokinetic and dose-escalation study of the carboplatin/paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combination, patients were randomly assigned to receive paclitaxel either as a 1-hour or a 3-hour infusion. The 1-hour infusion was feasible, with maximum tolerated doses similar to those previously reported for a 3-hour infusion. Using patients' age, height, plasma creatinine, and plasma creatine kinase provided an improved estimate of the glomerular filtration rate compared with the more traditional creatinine-based formulas according to population analysis of data derived from glomerular filtration rate estimates performed by an isotope method. Studies of the p53 gene sequence of ovarian tumors at diagnosis suggest that p53 mutations are a potent predictor of response to subsequent treatment with carboplatin.
Author(s): Calvert, A. H., Ghokul, S., Al-Azraqi, A., Wright, J., Lind, M., Bailey, N., Highley, M., Siddiqui, N., Lunec, J., Sinha, D., Boddy, A. V., Roberts, F., Fenwick, J.
Publication type: Article
Publication status: Published
Journal: Seminars in Oncology
Year: 1999
Volume: 26
Issue: 1 supplement 2
Pages: 90-94
Print publication date: 01/02/1999
ISSN (print): 0093-7754
ISSN (electronic): 1532-8708
URL: http://cat.inist.fr/?aModele=afficheN&cpsidt=1749460
PubMed id: 10190788
